CC-92252 / BMS - LARVOL DELTA

Evidence of recurrent selection of mutations commonly found in SARS-CoV-2 variants of concern in viruses infecting immunocompromised patients (AIDS 2022) - "The nsp6:L37F and nsp6:del106-108 mutations fluctuated over time and in the last timepoint, L37F was predominant and the deletion was not detected... Our data suggest that immunocompromised hosts are central to the genesis and emergence of SARS-CoV-2 genomic variations that impact viral immune evasion and are present in VOCs throughout the COVID-19 pandemic, a phenomenon that requires continuous monitoring."

Clinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Infectious Disease • Leukemia • Novel Coronavirus Disease • Oncology • Respiratory Diseases • Transplantation

"Study of another Treg-directed Fc-IL-2 mutein fusion protein, CC-92252, also terminated $BMY https://t.co/5NvJoVGoqf" (@JacobPlieth)

IL2

A Safety Study of CC-92252 in Healthy Adult Subjects and Adult Subjects With Psoriasis (clinicaltrials.gov) - P1; N=131; Terminated; Sponsor: Celgene; Active, not recruiting ➔ Terminated; Did not meet progression criteria

Clinical • Trial termination • Dermatology • Immunology • Psoriasis

A Safety Study of CC-92252 in Healthy Adult Subjects and Adult Subjects With Psoriasis (clinicaltrials.gov) - P1; N=112; Active, not recruiting; Sponsor: Celgene; Recruiting ➔ Active, not recruiting

Enrollment closed • Dermatology • Immunology • Psoriasis

A Safety Study of CC-92252 in Healthy Adult Subjects and Adult Subjects With Psoriasis (clinicaltrials.gov) - P1; N=133; Recruiting; Sponsor: Celgene; Trial completion date: Jan 2021 ➔ Sep 2022; Trial primary completion date: Jan 2021 ➔ Sep 2022

Clinical • Trial completion date • Trial primary completion date • Dermatology • Immunology • Psoriasis